Phase 1Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsored by Stemline Therapeutics, Inc.
About this study
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Enrolling at this location
Winship Cancer Institute, Emory University
Atlanta, Georgia
I'm interestedThis study also enrolls at 36 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.